US5744153A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liquid delivery compositions
Assignee: Tolmar Therapeutics Inc
•
Filing: 1997-06-09
•
Granted: 1998-04-28
•
Expires: 2017-06-09
Abstract
Abstract Improved biocompatible liquid delivery compositions, which are useful for the formation of sustained release delivery systems for active agents, are provided. The compositions include liquid formulations of a biocompatible polymer or prepolymer in combination with a controlled release component. The controlled release component includes an active agent. These compositions may be introduced into the body of a subject in liquid form which then solidify or cure in situ to form a controlled release implant or a film dressing. The liquid delivery compositions may also be employed ex situ to produce a controlled release implant. Methods of forming a controlled release implant and employing the liquid formulations in the treatment of a subject are also provided.
Inventors
- 👤 Gerald L. Yewey
- 👤 Nancy L. Krinick
- 👤 Richard L. Dunn
- 👤 Michael L. Radomsky
- 👤 Gerbrand Brouwer
- 👤 Arthur J. Tipton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 12:05
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/20; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/4427; A61K31/4439; A61K31/47; A61K31/485; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K38/00; A61K38/04; A61K38/08; A61K38/09; A61K38/16; A61K38/17; A61K38/22; A61K38/27; A61K47/00; A61K47/30; A61K47/34; A61K47/50; A61K47/51; A61K47/56; A61K47/58; A61K47/59; A61K47/593; A61K47/69; A61K47/6903; A61K47/6921; A61K49/00; A61K49/001; A61K49/0013; A61K49/0017; A61K49/0019; A61K49/0021; A61K49/0036; A61K49/005; A61K49/0054; A61K49/0063; A61K49/0069; A61K49/0089; A61K49/0091; A61K9/10; A61K9/14; A61K9/141; A61K9/146; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5026; A61K9/5036; A61K9/5042; A61K9/5047; A61L; A61L26/00; A61L26/0009; A61L26/0019; A61L26/0061; A61L26/0066; A61L26/0085; A61L27/00; A61L27/14; A61L27/18; A61L27/50; A61L27/56; A61L31/00; A61L31/04; A61L31/06; A61L31/14; A61L31/146; A61L31/16; A61K47/42; A61L2300/00; A61L2300/60; A61L2300/602; A61L2300/604; A61L2300/62; A61L2400/00; A61L2400/06; Y; Y10; Y10S; Y10S525/00; Y10S525/937; Y10S977/00; Y10S977/70; Y10S977/773; Y10S977/774; Y10S977/778; Y10S977/783; Y10S977/902; Y10S977/904; Y10S977/906; Y10S977/907; Y10S977/915; Y10S977/918
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
152 words
A method for the in situ formation of a controlled release implant in or on a subject, comprising: administering to the subject a flowable composition, and allowing the flowable composition to contact a body fluid of the subject or an aqueous medium to form the controlled release said implant within or on the subject; wherein, the flowable composition comprises an organic solvent in which is dissolved a thermoplastic polymer, and in which is suspended a multiplicity of solid microstructures incorporating an active agent; the organic solvent is biocompatible, and has a solubility range of miscible to dispersible in the aqueous medium or the body fluid; the thermoplastic polymer is biocompatible, biodegradable, soluble in the organic solvent, and insoluble in the aqueous medium or the body fluid; the solid microstructures are insoluble in the organic solvent, the aqueous medium and the body fluid, and are composed of a biocompatible polymer which is biodegradable.
Claim 2
Independent Claim
152 words
A method for the in situ formation of a controlled release implant in or on a subject, comprising: administering to the subject a flowable composition, and allowing the flowable composition to contact a body fluid of the subject or an aqueous medium to form the controlled release said implant within or on the subject; wherein, the flowable composition comprises an organic solvent in which is dissolved a thermoplastic polymer, and in which is suspended a multiplicity of solid microstructures incorporating an active agent; the organic solvent is biocompatible, and has a solubility range of miscible to dispersible in the aqueous medium or the body fluid; the thermoplastic polymer is biocompatible, biodegradable, soluble in the organic solvent, and insoluble in the aqueous medium or the body fluid; the solid microstructures are insoluble in the organic solvent, the aqueous medium and the body fluid, and are composed of a biocompatible polymer which is biodegradable.
Claim 3
Independent Claim
131 words
A method of treating a subject with an active agent, comprising: inserting into the subject a controlled release implant which is formed outside the subject by contacting a flowable composition with an aqueous medium; wherein, the flowable composition comprises an organic solvent in which is dissolved a thermoplastic polymer and in which is suspended a multiplicity of solid microstructures incorporating an active agent; the organic solvent is biocompatible, and has a solubility range of miscible to dispersible in the aqueous medium; the thermoplastic polymer is biocompatible, biodegradable, soluble in the organic solvent, and insoluble in the aqueous medium and a body fluid of the subject; the solid microstructures are insoluble in the organic solvent, the aqueous medium and the body fluid, and are composed of a biocompatible polymer which is biodegradable.
Claim 4
Independent Claim
131 words
A method of treating a subject with an active agent, comprising: inserting into the subject a controlled release implant which is formed outside the subject by contacting a flowable composition with an aqueous medium; wherein, the flowable composition comprises an organic solvent in which is dissolved a thermoplastic polymer and in which is suspended a multiplicity of solid microstructures incorporating an active agent; the organic solvent is biocompatible, and has a solubility range of miscible to dispersible in the aqueous medium; the thermoplastic polymer is biocompatible, biodegradable, soluble in the organic solvent, and insoluble in the aqueous medium and a body fluid of the subject; the solid microstructures are insoluble in the organic solvent, the aqueous medium and the body fluid, and are composed of a biocompatible polymer which is biodegradable.
Claim 5
Dependent Claim
19 words
The method of claim 1 wherein administering the composition comprises spraying, painting or squirting the composition on the tissue.
Claim 6
Dependent Claim
45 words
The method of claim 1, wherein the biocompatible, thermoplastic polymer is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthoesters, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(amino acids), copolymers thereof, terpolymers thereof, and mixtures thereof.
Claim 7
Dependent Claim
20 words
The method of claim 1, wherein the thermoplastic polymer is selected from the group consisting of polylactides, polycaprolactones, and polyglycolides.
Claim 8
Dependent Claim
66 words
The method of claim 1, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, glycerol, tetraglycol, glycerol formal, solketal, ethyl acetate, ethyl lactate, ethyl butyrate, dibutyl malonate, tributyl citrate, tri-n-hexyl acetylcitrate, diethyl succinate, diethyl glutarate, diethyl malonate, triethyl citrate, triacetin, tributyrin, diethyl carbonate, propylene carbonate, acetone, methyl ethyl ketone, dimethyl sulfoxide, dimethyl sulfone, tetrahydrofuran, caprolactam, N,N-diethyl-m-toluamide, 1-dodecylazacycloheptan-2-one, 1,3-dimethyl-3,4,5,6-tetrohydro-2(1H)-pyrimidinone, and any combination thereof.
Claim 9
Dependent Claim
28 words
The method of claim 1, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, ethyl lactate, dimethyl sulfoxide, propylene carbonate, and any combination thereof.
Claim 10
Dependent Claim
67 words
The method of claim 1, wherein the active agent is selected from the group consisting of an antibacterial agent, antifungal agent, antiviral agent, anti-inflammatory agent, antiparasitic agent, anti-neoplastic agent, analgesic agent, anesthetic agent, antipsychotic agent, vaccine, central nervous system agent, growth factor, hormone, antihistamine, osteoinductive agent, cardiovascular agent, anti-ulcer agent, bronchodilating agent, vasodilating agent, birth control agent, antihypertensive agent, anticoagulant, antispasmodic agent, fertility-enhancing agent, and combinations thereof.
Claim 11
Dependent Claim
16 words
A method according to claim 7 or 8, wherein the microstructures are microparticles, microcapsules or nanoparticles.
References Cited (Backward Citations)
US2155658A
Cited
US3887699A
Cited
US4450150A
Cited
GB2017113A
Cited
US4265247A
Cited
US4408023A
Cited
US4451452A
Cited
US4721613A
Cited
US4622219A
Cited
US4631188A
Cited
US4685883A
Cited
WO1985002092A1
Cited
US4818542A
Cited
US4745160A
Cited
US5049386A
Cited
US4933182A
Cited
US4780320A
Cited
US4919939A
Cited
US4962091A
Cited
US5227157A
Cited
US4981696A
Cited
US4861627A
Cited
US5013553A
Cited
US4912141A
Cited
US4897268A
Cited
US5192741A
Cited
US4938763A
Cited
US4938763B1
Cited
US5340849A
Cited
US5278202A
Cited
US5278201A
Cited
US5324520A
Cited
US5019400A
Cited
US5077049A
Cited
US5368859A
Cited
US5324519A
Cited
US5271961A
Cited
US5188837A
Cited
US5238714A
Cited
US5149543A
Cited
US5368858A
Cited
US5326568A
Cited
US5176907A
Cited
EP0537559A1
Cited
EP0539751A1
Cited
EP0560014A1
Cited
EP0586838A1
Cited
EP0649662A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-04-27 | 2001-10-27 | 2002-04-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-04-27 | 2005-10-27 | 2006-04-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-04-27 | 2009-10-27 | 2010-04-28 | $7700.00 | Window Closed / Lapsed |